BRKR Stock Risk & Deep Value Analysis
Bruker Corp
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About BRKR Stock
We analyzed Bruker Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran BRKR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
BRKR Risk Analysis & Red Flags
Risk Matrix
Overall
Moderate
Financial
Medium
Market
High
Competitive
Medium
Execution
Medium
Regulatory
Low
Upcoming Risk Events
- 📅
Further weakening of global demand in key customer segments
- 📅
Escalation of tariffs or trade tensions impacting supply chain and sales
- 📅
Continued decline in NIH budgets affecting research funding
- 📅
Intensified competitive pressure or disruptive technology from rivals
Unlock BRKR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Bruker Corp (BRKR) Do?
Market Cap
$5.07B
Sector
Healthcare
Industry
Medical Devices
Employees
11,396
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
Visit Bruker Corp WebsiteInvestment Thesis
Bruker Corp. is a high-quality, specialized scientific instrument company with a durable narrow moat, well-positioned for stable, long-term growth as global research and development spending recovers. While it lacks the characteristics for 10x growth, it offers exposure to essential scientific infrastructure, potentially benefiting from an eventual turnaround in demand and the impact of its cost savings initiatives.
Is BRKR Stock Undervalued?
Unlock the full AI analysis for BRKR
Get the complete DVR score, risk analysis, and more
BRKR Price Targets & Strategy
12-Month Target
$42.50
Bull Case
$50.00
Bear Case
$30.00
Valuation Basis
Based on a 20x forward P/E multiple applied to the midpoint of FY26 EPS guidance of $2.125 ($2.10-$2.15).
Entry Strategy
Dollar-cost average between $30-$34, targeting dips below the current price ($33.35) as potential support levels amid short-term volatility.
Exit Strategy
Take profit at $45-$50.00 if fundamental improvements are evident. Stop loss at $29.00 to limit downside risk given current market sentiment and organic declines.
Portfolio Allocation
2-4% for a moderate-to-conservative risk tolerance, primarily for long-term stability and exposure to specialized scientific tools, not for aggressive growth.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is BRKR Financially Healthy?
Valuation
P/E Ratio
-222.17
Forward P/E
38.10
PEG Ratio
2.00
Profitability
Net Margin
-0.25%
Return on Equity
13.56%
Revenue Growth
-0.20%
EPS
$0.59
Balance Sheet
Current Ratio
1.73
Quick Ratio
0.87
Debt/Equity
0.75
Other
Beta (Volatility)
1.19
Dividend Yield
0.60%
Does BRKR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
3 Identified
Bruker's moat is durable due to its specialized intellectual property in high-precision scientific instruments, which are expensive and complex to develop and replace, leading to high switching costs for established customers. The company also benefits from efficient scale in its niche markets.
Moat Erosion Risks
- •Intense R&D investment by competitors leading to technological leapfrogs
- •Changes in global research funding priorities or academic budgets
- •Economic downturns impacting capital expenditure for scientific equipment
BRKR Competitive Moat Analysis
Sign up to see competitive advantages
BRKR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, as general market sentiment reflects current performance and guidance rather than significant buzz or excitement.
Institutional Sentiment
Neutral to Negative, with recent analyst downgrades (Stifel, Citi, Barclays) and a 'Hold' consensus despite some 'Buy' ratings.
Insider Activity (Form 4)
VP Mark Munch sold 2,000 shares at $49.20/share, totaling $98,400, within the last 90 days. No CEO/CFO activity reported. Insiders retain a significant 27.3% ownership.
Options Flow
Normal options activity observed; no specific unusual put/call ratio or large institutional block trades were reported in the provided data.
Earnings Intelligence
Next Earnings
2026-05-06
Surprise Probability
Medium
Historical Earnings Pattern
The stock recently dropped (15.82% 1-month return) after Q4 2025 earnings due to an EPS miss and weak guidance, suggesting sensitivity to earnings performance and forward outlook.
Key Metrics to Watch
Competitive Position
Top Competitor
Thermo Fisher Scientific (TMO)
Market Share Trend
Stable in its niche segments but showing organic revenue decline overall, indicating challenges in gaining ground in the current demand environment.
Valuation vs Peers
Bruker's forward P/E of 17.07 is generally in line with or slightly below some larger, more diversified scientific instrument peers, but higher than justified by its recent organic decline and margin pressure compared to high-growth sectors.
Competitive Advantages
- •Proprietary technology and strong intellectual property in specialized instruments (e.g., NMR, Mass Spectrometry)
- •High switching costs for customers due to specialized equipment and workflow integration
- •Established global sales and service network
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive BRKR Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (May 6, 2026)
- •Impact of $100M+ cost savings program on 2026 margins
Medium-Term (6-18 months)
- •Potential recovery in academic, government, and biopharma spending post-2026
- •Stabilization of demand in the China market
Long-Term (18+ months)
- •Continued innovation in highly specialized scientific instruments (e.g., advanced NMR, Mass Spec)
- •Leveraging installed base for recurring revenue and service contracts
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for BRKR?
- ✓
Consistent reacceleration of organic revenue growth across all segments (especially above 5%)
- ✓
Demonstrable expansion in non-GAAP operating margins driven by efficiency and favorable mix
- ✓
Positive revisions to full-year guidance and improvement in book-to-bill ratios
Bull Case Analysis
See what could go right with Premium
Competing with BRKR
See how Bruker Corp compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Bruker Corp BRKR | $5.1B | 0.5 | -222.2 | $977.2M | -0.3% | -0.2% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $161.1B | 0.2 | 20.2 | $17.6B | 12.4% | -1.7% | Compare → |
UnitedHealth Group Inc UNH | $300.6B | 0.5 | 17.3 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Bruker Corp (BRKR)?
As of March 23, 2026, Bruker Corp has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Bruker Corp?
Bruker Corp's market capitalization is approximately $5.1B. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Bruker Corp use?
BRKR is the ticker symbol for Bruker Corp. The company trades on the NMS.
What is the risk level for BRKR stock?
Our analysis rates Bruker Corp's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of BRKR?
Bruker Corp currently has a price-to-earnings (P/E) ratio of -222.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Does Bruker Corp pay a dividend?
Yes, Bruker Corp pays a dividend with a current yield of approximately 0.60%.
Is Bruker Corp's revenue growing?
Bruker Corp has reported revenue growth of -0.2%. Revenue has been declining, which warrants closer examination.
Is BRKR stock profitable?
Bruker Corp has a profit margin of -0.3%. The company is currently unprofitable.
How often is the BRKR DVR analysis updated?
Our AI-powered analysis of Bruker Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 23, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for BRKR (Bruker Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.